CA2677201C — Solid preparation comprising alogliptin and pioglitazone
Assigned to Takeda Pharmaceutical Co Ltd · Expires 2015-11-17 · 10y expired
What this patent protects
A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which may be useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution…
USPTO Abstract
A solid preparation containing compound (I), wherein the definition of compound (I) is as defined in the description, and pioglitazone, which may be useful as a therapeutic drug for diabetes and the like and superior in the dissolution property, chemical stability and dissolution stability, is provided. A solid preparation containing the following first and second parts: (1) the first part containing compound (I) or a salt thereof and, as the first excipient, sugar or sugar alcohol, and (2) the second part containing pioglitazone or a salt thereof and, as the second excipient, sugar or sugar alcohol.
Drugs covered by this patent
- Amaryl (GLIMEPIRIDE) · Sanofi
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.